

Special Issue

Therapeutic Mechanisms of Photobiomodulation

Message from the Guest Editors

This Special Issue of *Biomedicines* will be an evaluation of past, novel and emerging evidence for the therapeutic mechanisms of photobiomodulation. The Special Issue will assemble papers that cover many areas of previous and current scientific research underpinning the molecular mechanisms of photobiomodulation and its translation into therapeutic applications. The therapeutic effects of photobiomodulation appear to be mediated through pleiotropic pathways and mechanisms, directly, systemically, and by the abscopal modulation of cellular metabolism, gut–brain axis etc. The aim of this Issue is to bring together state-of-the-art papers in these areas of research, as well as the more traditional areas of photobiomodulation therapy in pain, wounds, and inflammatory arthritis. There are many fields of research that intersect with photobiomodulation, including photophysics, photobiology, and translational medical research. Bringing together this research under the theme of therapeutic mechanisms of photobiomodulation will allow for an evidence-supported level of recognition of PBM, and has the potential to accelerate the translational uptake of this therapy.

Guest Editors

Dr. Ann Liebert

Sydney Adventist Hospital, Wahroonga, Australia

Prof. Dr. Liisa Laakso

Mater Research, South Brisbane, QLD, Australia

Prof. Dr. Hosen Kiat

1. ANU College of Health and Medicine, Australian National University, Canberra, ACT 2601, Australia
2. Faculty of Medicine, Human and Health Sciences, Macquarie University, Macquarie Park, NSW 2109, Australia
3. NICM Health Research Institute, Western Sydney University, Sydney, NSW 2000, Australia

Deadline for manuscript submissions

closed (31 October 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/143520

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).